Clinical Implications of the Associations Between Intestinal Microbiome and Colorectal Cancer Progression

This article was published in the following Dove Press journal:
Cancer Management and Research

Yongkang Chen¹
Yong Yang¹
Jin Gu¹⁻³

¹Department of Gastrointestinal Surgery III, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, People's Republic of China; ²Department of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing 100144, People's Republic of China; ³Peking-Tsinghua Center for Life Science, Tsinghua University, Beijing 100142, People's Republic of China

Abstract: Intestinal microbiome influences host immunity and several diseases, including cancer, in their areas of colonization. Microbial dysbiosis and over-colonization of specific microbes within the colorectal mucosa can impact the progress of carcinogenesis. Investigations initially focused on the mechanisms by which the intestinal microbiome initiates or promotes the development of colorectal cancer, including DNA damage, induction of chromosomal instability, and regulation of host immune responses. Some studies on the clinicopathological features have reported that specific strains present at high abundance are associated with advanced stage and positive lymph nodes in colorectal cancer. In this context, we reviewed the relationship between the intestinal microbiome and the clinical features (patient age, disease staging, prognosis, etc.) of patients with colorectal cancer, and evaluated the potential pathogenesis caused by the intestinal microbiome in disease progress. This article assessed whether changes in distinct species or strains occur during the period of cancer advancement. Overall, age grouping does not bring about significant differences in the constitution of microbiome. The disease stages show their distinct distribution in some species and strains. Oncogenic species are generally enriched in patients with poor prognosis, including low infiltration of CD3⁺ T cells, poor differentiation, widespread invasion, high microsatellite instability, CpG island methylator phenotype, BRAF mutation, short overall survival, and disease-free survival. The implications of those changes we discussed may assist in comprehensive understanding of the tumorigenesis of colorectal cancer from a microbiological perspective, finding potential biomarkers for colorectal cancer.

Keywords: colorectal cancer, intestinal microbiome, patient age, disease stage, prognosis

Introduction

Recent research on human symbiotic microbiome has revealed its significant impact on human health. Associations have been shown between microbiota and diabetes, liver diseases, hypertension, and chronic kidney diseases¹⁻³. The microbiota also plays a significant role in cancer development through inflammation, DNA damage, and cellular immunity⁴⁻⁹. Since the colorectum is the area most densely populated by the microbiota in vivo, the roles of the intestinal microbiome in the processes of colorectal cancer development are of scientific interest.¹⁰

The latest Global Cancer Incidence, Mortality, and Prevalence (GLOBOCAN) statistics indicate that colorectal cancer is the second leading cause of cancer-associated deaths worldwide.¹¹ Lifestyle and diet are closely related to sporadic colorectal cancer.¹² Improper diets alter the composition, abundance, and balance of

Correspondence: Jin Gu
Tel +86-010-88196238
Email zlgui@bjmu.edu.cn

the intestinal microbiome, destabilizing the stasis between microbiota and the intestinal epithelium, resulting in intestinal inflammation and cancer.¹³ Even familial colorectal polyposis with a genetic predisposition may develop early carcinogenesis due to epithelial damage caused by interactions between specific intestinal bacterial types and interleukin-17.¹⁴ Some investigators have questioned the vital role of the microbiome, reporting intestinal microbial changes are accompanied consequences in tumor formation.¹⁵ However, mice have been shown to be more susceptible to colorectal dysplasia after being fed feces from patients with colorectal cancer.¹⁶

The intestinal microbiome can not only initiate the tumorigenesis of colonic epithelial cells but promote the growth and metastasis of cancers that have already developed. Specific colonizing bacteria identified in the cancerous colorectal mucosa have been shown to be diverse from those found in mucosa adjacent to the tumor, in patients with benign colorectal diseases, and in healthy individuals.^{17,18} Moreover, recent reports addressed that colonization of specific species was associated with positive regional lymph nodes, vessel carcinoma embolus, and gene mutations.^{19,20} These relations give those distinctive gut bacteria and their metabolites the potential to become non-invasive biomarkers of colorectal cancer. Recently, this review focused on recent changes in the composition, abundance, and balance of intestinal microbiome in colorectal cancer and their relationship to the clinical feature (age, stage, and prognosis) of patients (Table 1), to explore the evidence of their influence on the development of colorectal cancer.

Literature Search

Characteristics of Intestinal Microbiota in Colorectal Cancer

Analysis of the 16S rRNA gene sequence in feces or colorectal tissues has identified distinctive changes in intestinal microbiota. The overall microbiota diversity (i.e., the number of different taxa) declined in patients with colorectal cancer; however, the microbial diversity in those patients was not significantly different compared to that in the control group (i.e., the distribution of taxa).²¹ Comparison of taxonomic groups based on phyla between cancer patients and control volunteers revealed significant enrichment of *Fusobacteria* (to the greatest extent), *Proteobacteria*, and *Bacteroidetes* in CRC patients. In contrast, *Actinobacteria* and *Firmicutes* were relatively depleted.^{18,22} Another study reported the enrichment of *Fusobacterium*, *Porphyromonas*, and *Atopobium* in colorectal

cancer.²¹ *Firmicutes* depletion was commonly observed in several studies. *Clostridia* was the most significantly reduced among Firmicutes compared to the declines in *Coprococcus* and *Lachnospiraceae*.^{18,21} *Coprococcus* ferments dietary fiber and other complex carbohydrates into butyric acids, the primary metabolite that inhibits colonic inflammation and tumorigenesis.²¹ A Chinese study reported a relative reduction in butyrate-producing bacteria (*Clostridiaceae*, *Ruminococcus*, etc.), suggesting that these bacteria could protect the colorectal mucosa from carcinogenesis.²³

Some studies have focused on distinctive microbiota in colorectal cancer according to species taxonomy. A metagenomic classifier for colorectal cancer detection revealed that the four most discriminative species included two *Fusobacterium* species, *Porphyromonas asaccharolytica* and *Peptostreptococcus stomatis*, and two subspecies, *F. nucleatum vincentii* and *F. nucleatum animalis*, which distinguished colorectal cancer with an accuracy of 0.63.²² A study that characterized bacterial communities in stool samples found that colorectal cancer-associated bacteria belonged to taxa commonly associated with periodontal disease,^{22,24} including *Porphyromonas asaccharolytica*, *Fusobacterium nucleatum*, *Parvimonas micra*, *Peptostreptococcus stomatis*, *Gemella spp.*, and an unclassified *Prevotella*.²²

Integrated microbial genome (IMG of species), operational taxonomic unit (OTU), and metagenomic linkage group (MLG) analysis revealed three oral pathogens, *Parvimonas micra*, *Fusobacterium nucleatum*, and *Solobacterium moorei* to be enriched in colorectal cancer tissue, while over-colonization of *Peptostreptococcus stomatis* was only detected by two of these methods.²⁵ A multicenter metagenome sequencing study among China, Austria, the United States, Germany, and France confirmed that seven distinctive bacteria are over-represented in colorectal cancer (*Bacteroides fragilis*, *Fusobacterium nucleatum*, *Porphyromonas asaccharolytica*, *Parvimonas micra*, *Prevotella intermedia*, *Alistipes finegoldii*, and *Thermanaerovibrio acidaminovorans*).²⁶ Besides, levels of *Peptostreptococcus anaerobius* were elevated in colorectal cancer mucosa compared to those in colorectal polyps.²⁷ Discrepancy analysis revealed significant enrichment of *Enterococcus faecalis*, Enterotoxigenic *Bacteroides fragilis* (ETBF) in carcinoma tissues compared to that in tumor-adjacent tissues in colorectal cancer.²⁸ In contrast, levels of *Eubacterium rectale* and *Faecalibacterium prausnitzii* (both butyric acid-producing bacteria) were reduced by four-fold in colorectal

Table 1 The Bacteria Discussed in This Review and Their Connections to Colorectal Cancer

Increase or Reduction	Phyla-Class	Genus or Species (Subspecies)	Metabolism Effect	Mechanism	Clinicopathologic Features	Prognosis
Over-colonisation	Fusobacteria ^{17,18,22} -Fusobacterium ^{17,31}	<i>Fusobacterium nucleatum</i> ^{9,18,22,25,26,31-36,33,37,43,46,48,49} (subsp. <i>Vincentii</i> , subsp. <i>animalis</i> ²²)	/	Less E-cadherin on tumor cells ⁹ Less infiltrating T cells ⁹ More N-cadherin and nanog on tumor cells ⁹ NK cells inhibition via Fap2 protein ³⁵ E-cadherin/ β -catenin pathway ³⁶ Upregulation of REG3A, REG1A and REG1P ⁴⁹	NS between stages in Germany ²² Abundant in early-stage ²⁶ Regional lymph node metastasis ³¹ Liver metastasis ³² MSI-H, CIMP-high, LINE-1 hypomethylation, and BRAF mutation ³³ Abundant at the ascending and transverse colons (compared to cecum, spleen to the sigmoid colon, sigmoid colon, and rectum) ³³ A linear trend from rectal cancer (2.5%) to cecal cancer (11%) ³⁴ Younger and black ethnicity patients in South African ³⁷ Over-colonization in stage III rather than I and II ³⁷ NS between ≤ 60 and >60 in Chinese ⁴³ Positive lymph node status and advanced tumor invasion ⁴³ Peak in stage II ³³ abundant in pT3 rather than pT1-2 ³³ NS between pN stages ³³ Poorly differentiated carcinoma ⁴⁶ Significant increase in inflammatory and DNA damage pathways ⁴⁹	Poorer overall survival and disease-free survival ⁴³ High disease-specific and disease-free survival in stage III or IV patients ⁴⁸
	Clostridia— Clostridiales	<i>Peptostreptococcus stomatis</i> ^{18,22,25} <i>Peptostreptococcus anaerobius</i> ²⁷	/	/	/	/
	Clostridia— Clostridiales	<i>Clostridium symbiosum</i> ^{22,42,43}	/	/	Peaking in stage II or III ⁴² NS between ≤ 60 and >60 in Chinese ⁴³ Widespread tumor invasion ⁴³	/

(Continued)

Table 1 (Continued).

Increase or Reduction	Phyla-Class	Genus or Species (Subspecies)	Metabolism Effect	Mechanism	Clinicopathologic Features	Prognosis
	Clostridia—Clostridiales	<i>Parvimonas micra</i> ^{18,22,25,26}	/	/	Abundant in early-stage ²⁶	/
	Bacteroidetes—Bacteroidetes	<i>Enterotoxigenic Bacteroides fragilis</i> (ETBF) ^{28,37–40,43,47}	/	IL-17-dependent NF-κB activation in the colon epithelium ³⁹ CXCR2 ⁺ immature myeloid cells ³⁹ (Bft and IL-17) Activated colonic epithelial cells promote MDSC differentiation ⁴⁰	Higher in stage III and IV than stage I and II ³⁷ NS between ≤60 and >60 in Chinese ⁴³ An increasing trend from stage I to stage IV ³⁸ Low CD3 ⁺ T cell infiltration ⁴⁷	/
	Bacteroidetes—Bacteroidetes	<i>Bacteroides fragilis</i> ^{22,26,42,43,46,47}	/	/	Abundant in early-stage ²⁶ Peaking in stage II or III ⁴² Intestinal extramural vascular invasion ⁴⁶	Poorer overall survival and disease-free survival ⁴³
	Bacteroidetes—Bacteroidetes	Unclassified <i>Prevotella</i> ²² <i>Prevotella intermedia</i> ^{26,47}	/	/	Abundant in early-stage ²⁶ Low CD3 ⁺ T cell infiltration ⁴⁷	Shorter survival compared to high CD3 ⁺ T cell infiltration ⁴⁷
	Bacteroidetes—Bacteroidetes	<i>Alistipes finegoldii</i> ²⁶	/	/	Abundant in early-stage ²⁶	/
	Bacteroidetes ¹⁸ —Bacteroidales	<i>Porphyromonas asaccharolytica</i> ^{18,21,22,26}	/	/	Abundant in early-stage ²⁶	/
	Firmicutes—Bacilli	<i>Enterococcus faecalis</i> ^{28,49}	/	Upregulation of CXCL10 and BMI1 ⁴⁹	MSI-H, CIMP-high ⁴⁹ Significant increase in inflammatory and DNA damage pathways ⁴⁹	/
	Firmicutes ⁴⁶ —Bacilli	<i>F. streptococcus</i> spp. ⁴⁶ <i>F. Solobacterium</i> spp. ⁴⁶ <i>Clostridium X</i> ⁴⁶	/	/	Lymphatic vessel infiltration ⁴⁶ Poorly differentiated tumors ⁴⁶	/
	Firmicutes ¹⁷ —Bacilli	<i>Gemella</i> spp. ²²	/	/	/	/
	Firmicutes ¹⁷ —Bacilli	<i>Lactococcus</i> ¹⁷	/	/	/	/

Colonisation reduction	Firmicutes ¹⁷ – Clostridia	<i>Thermanaerovibrio acidaminovorans</i> ²⁶	/	/	Abundant in early-stage ²⁶	/
	Proteobacteria ¹⁸ – Gammaproteobacteria	<i>afaC</i> - or <i>pks</i> - <i>Escherichia coli</i> ^{37,44}	/	Inflammatory cells infiltration ⁴⁴	Over-colonization in stage T4 and M1 ⁴⁴ Relevance ratio peaks in stage II (I:43%, II:80%, III/IV:68%) ⁴⁴	/
	Proteobacteria ¹⁸ – Gammaproteobacteria	<i>Aggregatibacter</i> spp. ⁴⁶	/	/	KRAS mutations ⁴⁶	/
	Actinobacteria – Actinobacteria	<i>Atopobium</i> ²¹	/	/	/	/
	/	<i>Fretibacterium</i> ⁴⁷	/	/	Low CD3+ T cell infiltration ⁴⁷	Shorter survival compared to high CD3 ⁺ T cell infiltration ⁴⁷
	/	<i>Solobacterium moorei</i> ²⁵	/	/	/	/
	Firmicutes – Bacilli	<i>Streptococcus salivarius</i> ²²	/	/	/	/
	Firmicutes ⁴⁶ – Clostridia	<i>F. subdoligranulum</i> ⁴⁶	/	/	/	/
	Firmicutes – Clostridia	<i>Faecalibacterium prausnitzii</i> ^{29,30}	/	/	/	/
	Firmicutes – Clostridia	<i>Coproccoccus</i> ²¹ <i>Lachnospiraceae</i> ^{21,42}	/	Ferments dietary fiber and other complex carbohydrates into butyric acids ^{21,23}	Peaking in stage II or III ⁴²	/
	Firmicutes – Clostridia	<i>Eubacterium rectale</i> ^{22,23,29} <i>Eubacterium ventriosum</i> ^{22,23,25} <i>Eubacterium eligens</i> ^{22,23}	/	Butyric acid-producing ²³	/	/
	Firmicutes – Clostridia	Unclassified <i>Ruminococcus</i> sp. ^{22,23}	/	Butyrate-producing bacteria ²³	/	/
	Firmicutes – Clostridia	<i>Lachnospiraceae</i> ^{18,43}	/	/	Abundant in surviving patients (compared to non-surviving ones) ⁴³	/

(Continued)

Table 1 (Continued).

Increase or Reduction	Phyla-Class	Genus or Species (Subspecies)	Metabolism Effect	Mechanism	Clinicopathologic Features	Prognosis
	Proteobacteria- Alphaproteobacteria	<i>Methylobacterium</i> ⁴³ <i>Sphingomonas</i> ⁴³	/	/	Abundant in surviving patients (compared to non-surviving ones) ⁴³ Abundant in recurrence-free survival patients (compared to relapse ones) ⁴³	/
	Proteobacteria- Deltaproteobacteria	<i>Desulfotribrio</i> ⁴⁷	/	/	High CD3 ⁺ T cell infiltration ⁴⁷	Longer survival compared to low CD3 ⁺ T cell infiltration ⁴⁷
	Proteobacteria- Gammaproteobacteria	<i>Shewanella</i> ⁴³	/	/	Abundant in surviving patients (compared to non-surviving ones) ⁴³	/
	Proteobacteria ¹⁷ - Gammaproteobacteria	<i>Pseudomonas</i> ¹⁷ <i>Escherichia-Shigella</i> ¹⁷	/	/	/	/
	Spirochaetes- Spirochaetes	<i>Treponema</i> ⁴⁷	/	/	High CD3 ⁺ T cell infiltration ⁴⁷	Longer survival compared to low CD3 ⁺ T cell infiltration ⁴⁷
	/	<i>Alloprevotella</i> ⁴⁷	/	/	High CD3 ⁺ T cell infiltration ⁴⁷	Longer survival compared to low CD3 ⁺ T cell infiltration ⁴⁷

Abbreviations: NK, nature killer; BRAF, B-Raf proto-oncogene, serine/threonine kinase; KRAS, KRAS proto-oncogene, GTPase; CD, cluster of differentiation; ETBF, enterotoxigenic *Bacteroides fragilis*; TNM, tumor, node, metastasis stage system; pN, pathological lymph node stage; REG, regenerating islet derived protein; MSI-H, high microsatellite instability; CIMP, CpG island methylator phenotype; LINE-1, long interspersed nuclear element-1; NS, no significance; IL-17, interleukin-17; NF-κB, NF-kappaB inhibitor alpha; CXCR2, C-X-C motif receptor; Bft, *Bacteroides fragilis* toxin; MDSC, myeloid-derived suppressor cell; CXCL10, C-X-C motif ligand; BM11, B-cell-specific moloney leukemia virus insert site 1.

cancer patients compared to those in healthy control volunteers.^{29,30} Also, *Eubacterium ventriosum* showed higher levels in control microbiomes compared to those in colonic cancerous microbiomes.²⁵

Studies on *Fusobacterium* and the development of colorectal cancer are more abundant and thorough than those on any other cancer-related microbiome. DNA extracted from tissues in a cohort study revealed that the average total abundance of *Fusobacterium* in tumor samples was 415 times higher than those of matched healthy samples.³¹ Data from The Cancer Genome Atlas (TCGA) cohort showed that microorganisms present at the metastatic niche in the liver of patients with *Fusobacterium*-positive colorectal cancer were similar to those in the primary site, suggesting that the high relative abundance of *Fusobacterium* significantly increases the risk of liver metastasis.³² To exclude the potential confounding of the results due to a connection between *Fusobacterium* and liver tissues, *Fusobacterium* sequencing of primary hepatic carcinoma and metastatic tumor revealed deficient concentrations of *Fusobacterium* in primary liver cancer.³² *Fusobacterium nucleatum* appears to play a significant role in the *Fusobacterium* over-colonization of colorectal cancer mucosa.³¹ Rather than the other colorectal sites (cecum, spleen to the sigmoid colon, sigmoid colon, and rectum), *Fusobacterium nucleatum* appears to prefer the ascending and transverse colons.³³ The proportions of cancer patients with high relative abundances of *Fusobacterium nucleatum* increased from 2.5% (4/157) for rectal cancer to 11% (19/178) for cecal cancer, a linear and significant trend.³⁴ Compared with other sites, a reduction in the abundance of *Fusobacterium nucleatum* in the rectum, ascending colon, and cecum is often observed.³⁴ Consistent with the conclusions above, *Fusobacterium nucleatum* present in both the primary site and the corresponding metastatic tumor is more likely to be abundant in metastatic carcinomas of the cecum and ascending colon rather than in other sites.³² *Fusobacterium nucleatum* can inhibit positive immune from natural killer cells by Fap2 protein, inducing immune evasion.³⁵ Moreover, *Fusobacterium nucleatum* can utilize the E-cadherin/ β -catenin pathway to not only increase susceptibility to colorectal tumorigenesis but also exacerbate cancer cell proliferation and invasion.³⁶

In addition to *Fusobacterium nucleatum*, other strains with distinctive pathogenic factors have also attracted attention. The presence of enterotoxigenic *Bacteroides fragilis* (ETBF) and afaC or polyketide synthase (pks)-positive *Escherichia coli* (afaC- or pks- *E. coli*) was significantly associated with colorectal cancer.³⁷ *Bacteroides fragilis*

toxin (bft) is a toxic protein secreted by ETBF. Among diverse bft isoforms, bft-1, and bft-2 were more commonly detected in colorectal cancer cases (67.8%) than in the control group (34.4%).³⁸ A study utilizing transgenic mice found that CXCR2-positive multinuclear immature myeloid cells, which are recruited by the CXCL1 concentration gradient, cooperate with ETBF to initiate distal colonic tumorigenesis with IL-17-dependent NF- κ B activation in the epithelium of colorectal cancer tissue.³⁹ Colonic epithelial cells activated by Bft and IL-17 promote differentiation from macrophages to marrow-derived suppressor cells, which selectively upregulate arginase 1, nitric oxide synthase 2, and nitric oxide, finally inhibiting T cell growth.⁴⁰ Pks-positive *E. coli* can affect the progression of colorectal cancer by aggravating the infiltration of inflammatory cells.⁴¹

Intestinal Microbes in Colorectal Cancer Patients of Different Ages

Although a few recent studies have focused on the differences in intestinal microbiota between different age groups of patients with colorectal cancer, there are many clues. A similar enrichment was widely found between elderly (over 65 years of age) and younger (not over 65 years) patients in macrogene linkage group analysis, indicating that cancer-associated microbiota in diverse age groups shares common features.⁴² An investigation of the prognosis of colorectal cancer patients with over-representation of *Fusobacterium nucleatum*, *Bacteroides fragilis*, or *Clostridium*, observed no significant differences in the relative abundances of the 16S RNA levels of these bacteria in mucosal tissues between older (over 60 years) and younger patients (less than 60 years).⁴³ Fisher's exact tests of the correlation between high-abundance *Fusobacterium* and clinical factors revealed no association between *Fusobacterium* and patient age.³¹ However, a South African study reported that a high level of *Fusobacterium* colonization of colorectal cancer mucosa was more likely to be present in younger patients and those of black ethnicity.³⁷ Patients with low- and moderate-level colonization were predominantly between 60–70 years of age, while high-level colonization occurred mostly in patients 50–60 years of age, a statistically significant difference. About 31% of patients below 60 years of age, and 11% of those above 60 years had high levels of *Fusobacterium* colonization.³⁷ Differences in these findings between studies may be related to differences in ethnicity. Collectively, it appears that significant age-associated changes in the intestinal microbiome have not been observed.

Intestinal Microbes in Different Stages of Colorectal Cancer

Evidence suggests the presence of distinctive enrichment patterns of intestinal microbes according to the disease stage. A metagenomic sequencing study observed that seven of the 126 macrogene linkage groups (MLG-190, MLG-603, MLG-604, MLG-629, MLG-219, MLG-893, and MLG-1002; each MLG contained >100 genes) extracted from intestinal mucosa differed significantly between stages, peaking in patients with stage II or III colorectal cancer. These seven MLGs included gene groups shared by *Lachnospiraceae* bacterium, *Clostridium symbiosum*, and *Bacteroides* ssp.⁴² In the multi-national metagenomic sequencing project previously mentioned, *Bacteroides fragilis*, *Fusobacterium nucleatum*, *Porphyromonas asaccharolytica*, *Parvimonas micra*, *Prevotella intermedia*, *Alistipes finegoldii*, and *Thermanaerovibrio acidaminovorans*, which were distinctively enriched in 526 intestinal mucosa colorectal cancer samples, were more likely to be abundant in early-stage than late-stage disease.²⁶ In contrast, a metagenomic classifier study in Germany using species and subspecies of *Fusobacterium* detected microbe changes in both early-stage (I and II) and late-stage (III and IV) disease.²²

Furthermore, *Fusobacterium* are more likely to exhibit over-colonization in stage III colonic cancerous mucosa than in stage I or stage II disease.³⁷ Patients with pathological T3 stage (pT3, subserosal layer) disease had more copies of *Fusobacterium nucleatum* DNA in their tumor tissues compared to that in patients with stage T1 or T2 disease; however, a similar phenomenon was not observed for the pathological N stage.³³ The enrichment of *Fusobacterium nucleatum* peaks in AJCC stage II, which is correlated to highly differentiated colonic carcinoma.³³

Levels of ETBF are higher in stage III and IV disease than those in stage I and stage II colorectal cancer. A similar finding was also reported in a comparison between stage I and IV tumor-adjacent mucosa.³⁷ Moreover, the enterotoxin-encoding gene from *Bacteroides fragilis* was widely detected in the intestinal mucosa of patients with colorectal cancer, especially in those with stage III or IV disease, indicating that the bft gene may be a risk factor for advanced colorectal cancer. The rate of mucosal bft positivity in colorectal cancer showed an increasing trend between stage I and stage IV, although this trend was not statistically significant (72.7% and 100%, respectively).³⁸ In order to eliminate confounding in the microbiome detection resulting from preoperative antibiotics, bft detection was done among patients with

different stages of colorectal cancer undergoing mechanical preparations and not oral administration of antibiotics, with similar frequencies to those observed previously.³⁸

E. coli strain 11G5, a member of the B2 phylogroup, possesses a pks gene island encoding colibactin. It is considered the representative colon cancer-associated *E. coli* strain because of its high levels of colonization of the tumor-adjacent mucosa and cancerous tissues of patients with advanced cancer (T4) and liver metastasis (M1).⁴⁴ Compared to stage I (43%), B2 phylogroup *E. coli* is more likely to be detected in patients with stage II (80%) and stage III/IV (68%) disease. Cyclomodulin-positive *E. coli* strains throughout the entire colorectal mucosa or tumor tissues are found significantly more often in patients with TNM stage II (64%) and III/IV (67%) disease than in those with stage I disease (45%). The colonization level of *E. coli* in the mucosa or tumor had no impact on the ratio of these two *E. coli* strains.⁴⁴ The detection frequency in patients with stage II–IV colorectal cancer (59.3%) was significantly increased compared to that in patients with stage I disease (0.3%).⁴⁵

Intestinal Microbes and Prognosis in Patients with Colorectal Cancer

A growing body of evidence supports that intestinal microbes provide clues for colorectal cancer with poor prognosis. Analysis of the Chao diversity index showed a lower microbial community diversity in recurrence-free survival patients than that of patients with recurrent colorectal cancer.²¹ Analysis of the relative abundance of OTU demonstrated diverse compositions in the studied groups in patients with various prognoses (death, survival with relapse, and survival without relapse). *Proteobacteria* (33.8–49.4%), *Firmicutes* (16.9–22.7%), *Bacteroidetes* (21.1–27.9%), and *Fusobacterium* (3.38–10.8%) predominated in these groups.⁴³ High-abundance *Bacteroides* is associated with intestinal extramural vascular invasion of colorectal cancer. At the same time, *Firmicutes* is more likely to be connected to the presence of lymphatic vessel infiltration and *Proteobacteria*, *Aggregatibacter* spp. are related to KRAS mutations.⁴⁶ Wei et al reported a relatively higher abundance of *Shewanella*, *Methylobacterium*, *Faecalibacterium*, and *Sphingomonas* in surviving patients than that in non-surviving patients. *Methylbacteria* had a higher relative abundance in recurrence-free survival patients compared to that in patients with relapse.⁴³ Specific bacteria, including *Alloprevotella*, *Treponema*, and *Desulfovibrio* are significantly enriched in colorectal

cancer with high CD3⁺ T cell infiltration, whereas *Prevotella*, *Bacteroides*, and *Fretibacterium* are widely detected in cancers with low infiltration of CD3⁺ T cells. Furthermore, patients with high CD3 density had a significantly longer survival compared to that in patients with low CD3 density.⁴⁷

At the species level, *F. streptococcus* spp., *F. Solobacterium* spp., and *Clostridium* XI spp., which belong to *Firmicutes*, were more likely to exhibit over-colonization in poorly differentiated tumors, while *F. subdoligranulum* was detected at a low frequency.⁴⁶ In addition, a relative abundance above 0.52% in the colonic mucosa was defined as high-abundance *Fusobacterium nucleatum*, which was significantly associated with positive lymph node status and advanced tumor invasion. An abundance of 0.55% for *Clostridium* was only significantly associated with wide-spread tumor invasion.⁴³

The presence of *Fusobacterium*, especially *Fusobacterium nucleatum*, is highly correlated with severe invasion and poor prognosis of colorectal cancer. A higher relative abundance of *Fusobacterium* likely exists in poorly differentiated carcinoma.⁴⁶ Moreover, the relative abundance of *Fusobacterium nucleatum* is negatively correlated with E-cadherin on the surface of tumor cells and cancerous tissue-infiltrating T cells.⁹ In contrast, its relative abundance is positively correlated with N-cadherin and Nanog (a gene thought to maintain self-renewal of embryonic stem cells), suggesting the epithelial-mesenchymal transition of colorectal cancer cells.⁴⁸ Tumors with relatively abundant *Fusobacterium* are more likely to have regional lymph node metastasis, as indicated by the TNM score.³¹ Specifically, the proportions of patients with lymph node metastasis with high and low abundances of *Fusobacterium* were 74% and 45%, respectively.³¹ The colorectal cancer-specific mortality among patients with low (multivariate hazard ratio [HR]: 1.25; 95% confidence interval [CI]: 0.82–1.92) or high (HR:1.58, 95% CI: 1.04–2.39) loads of *Fusobacterium nucleatum* in their colonic mucosa was significantly higher than that in *Fusobacterium nucleatum*-negative patients.³³ A high *Fusobacterium nucleatum* load was associated with high microsatellite instability (MSI) (odds ratio: 5.22, 95% CI: 2.86–9.55) independent of the CpG island methylator phenotype (CIMP) and BRAF mutation status in multivariable logistic regression analysis. In this study, *Fusobacterium nucleatum* was also associated with CIMP-high, LINE-1 hypomethylation, and BRAF mutation.³³ Another study reported by Lennard showed that activation in inflammatory and DNA damage pathways was strong relative to *Fusobacterium*

nucleatum along with *Enterococcus faecalis*.⁴⁹ Colorectal cancer with dMMR/MSI has specific phenotypes, including proximal colon preference, poor differentiation, and lymphocyte enrichment^{50–52}. This study revealed that these two spaces might boost the disease development and progression via a transcriptional remodeling, including an increase of regenerating islet derived protein (REG3A, REG1A, and REG1P, high-abundance *Fusobacterium nucleatum*) and up-regulation of CXCL10 and BMI1 (high-abundance *E. faecalis*).⁴⁹ These findings indicate the association between the *Fusobacterium nucleatum* load in colorectal cancer tissue and poor survival. No or low fold-increase of *Fusobacterium nucleatum* in tumor tissues relative to the matched tumor-adjacent tissues in colorectal cancer resulted in a significant advantage in survival over patients with high fold-increases (no fold increase: <25, high fold-increase: >216). The median survival in patients with high- and low-fold *Fusobacterium nucleatum* was two and three years, respectively.⁵³ Both disease-specific and disease-free survival were higher in patients with stage III or IV colorectal cancer with a lower relative abundance of *Fusobacterium nucleatum* compared to survival in patients with higher relative DNA expression.⁴⁸

Wei et al reported a significantly more reduced three-year overall survival in patients with high abundances of *Bacteroides fragilis* and *Fusobacterium nucleatum* compared to that in patients with low abundances of these strains based on Kaplan-Meier analysis and Log rank tests of the relationship between patient survival and relative bacterial abundance in colorectal cancer tissues.⁴³ Besides, patients with a low abundance of *Clostridium* had a poor three-year overall survival, but the difference was not statistically significant.⁴³ Similarly, patients with high abundances of *Bacteroides fragilis* and *Fusobacterium nucleatum* had lower disease-free survival rates than those in low-abundance patients.⁴³ Cox regression and multivariate analysis showed that over-representation of *Bacteroides fragilis* (HR:2.010; 95% CI:1.020–3.961) and *Fusobacterium nucleatum* (HR:1.993; 95% CI:1.024–3.879) was associated with low overall survival after radical surgery in patients with colorectal cancer, which were independent predictors for three-year overall survival.⁴³

Conclusion

The intestinal microbiome involves in the development of colorectal cancer by altering the intestinal epithelial cells and the balance of the immune microenvironment. The species present in *Fusobacteria*, *Proteobacteria*, *Firmicutes*, *Bacteroidetes*, and *Clostridia* mainly play an indispensable

role in promoting the growth of tumors already present. The interaction between gut microbiota and colorectal cancer is multi-level and manifold. Different species in the microflora have a different impact on the malignant behaviors of the tumor. Molecular mutations (KRAS and BRAF), regional lymph node metastasis, and CD3⁺T cells inhibition are some of their potential targets. Their associations make assessing changes in the intestinal microbiome a convenient predictive tool for colorectal cancer. Useful biomarkers can influence treatment strategies for patients with colorectal cancer. Specific microbial can mediate the response to chemotherapy and radiotherapy, resulting in changing the prognosis of patients. Analysis of the gut microbiome offers the potential to develop non-invasive diagnostic tests that can serve as filtrating markers for improving treatment response. The potential of regulating the intestinal microbiome via changing the diet and using probiotics provides hope for reducing the risk of cancer development and improving the effectiveness of treatment.

Data Sharing Statement

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgment

Thanks to Jiajia Chen for sharing the Bacteria Classification Table.

Funding

This work was funded by Special Projects of Prevention and Control of Non-Communicable Diseases (2016YFC1302605) and Beijing Municipal Science & Technology Commission, Clinical Application and Development of Capital Characteristic (Z171100001017087).

Disclosure

All authors declare no conflicts of interest.

References

- Li Q, Gao Z, Wang H, et al. Intestinal immunomodulatory cells (T Lymphocytes): a bridge between gut microbiota and diabetes. *Mediators Inflamm*. 2018;2018:9830939. doi:10.1155/2018/9830939
- Altamirano-Barrera A, Uribe M, Chavez-Tapia NC, Nuno-Lambarri N. The role of the gut microbiota in the pathology and prevention of liver disease. *J Nutr Biochem*. 2018;60:1–8. doi:10.1016/j.jnutbio.2018.03.006
- Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. *Nat Rev Nephrol*. 2018;14(7):442–456. doi:10.1038/s41581-018-0018-2
- Schwabe RF, Jobin C. The microbiome and cancer. *Nat Rev Cancer*. 2013;13(11):800–812. doi:10.1038/nrc3610
- Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. *Cancer Cell*. 2012;21(4):504–516. doi:10.1016/j.ccr.2012.02.007
- Drewes JL, Housseau F, Sears CL. Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy. *Br J Cancer*. 2016;115(3):273–280. doi:10.1038/bjc.2016.189
- Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. *Science*. 2013;342(6161):971–976. doi:10.1126/science.1240537
- Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science*. 2013;342(6161):967–970. doi:10.1126/science.1240527
- Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science*. 2015;350(6264):1079–1084. doi:10.1126/science.aad1329
- Nakatsu G, Li X, Zhou H, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. *Nat Commun*. 2015;6:8727. doi:10.1038/ncomms9727
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424. doi:10.3322/caac.21492
- Wiseman M. The Second World Cancer Research Fund/American Institute for Cancer Research Expert Report. food, nutrition, physical activity, and the prevention of cancer: a global perspective. *Proc Nutr Soc*. 2008;67(3):253–256. doi:10.1017/S002966510800712X
- Han S, Gao J, Zhou Q, Liu S, Wen C, Yang X. Role of intestinal flora in colorectal cancer from the metabolite perspective: a systematic review. *Cancer Manag Res*. 2018;10:199–206. doi:10.2147/CMAR.S153482
- Dejea CM, Fathi P, Craig JM, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. *Science*. 2018;359(6375):592–597. doi:10.1126/science.aah3648
- Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. *Nat Rev Microbiol*. 2012;10(8):575–582. doi:10.1038/nrmicro2819
- Wong SH, Zhao L, Zhang X, et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. *Gastroenterology*. 2017;153(6):1621–1633 e1626. doi:10.1053/j.gastro.2017.08.022
- Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota disbiosis is associated with colorectal cancer. *Front Microbiol*. 2015;6:20. doi:10.3389/fmicb.2015.00020
- Baxter NT, Ruffin M, Rogers MA, Schloss PD. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Med*. 2016;8(1):37. doi:10.1186/s13073-016-0290-3
- Eklöf V, Lofgren-Burstrom A, Zingmark C, et al. Cancer-associated fecal microbial markers in colorectal cancer detection. *Int J Cancer*. 2017;141(12):2528–2536. doi:10.1002/ijc.31011
- Liang Q, Chiu J, Chen Y, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. *Clin Cancer Res*. 2017;23(8):2061–2070. doi:10.1158/1078-0432.CCR-16-1599
- Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. *J Natl Cancer Inst*. 2013;105(24):1907–1911. doi:10.1093/jnci/djt300
- Zeller G, Tap J, Voigt AY, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. *Mol Syst Biol*. 2014;10:766. doi:10.15252/msb.20145645
- Wang X, Ye T, Chen WJ, et al. Structural shift of gut microbiota during chemo-preventive effects of epigallocatechin gallate on colorectal carcinogenesis in mice. *World J Gastroenterol*. 2017;23(46):8128–8139. doi:10.3748/wjg.v23.i46.8128

24. Warren RL, Freeman DJ, Pleasance S, et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas. *Microbiome*. 2013;1(1):16. doi:10.1186/2049-2618-1-16
25. Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. *Gut*. 2017;66(1):70–78. doi:10.1136/gutjnl-2015-309800
26. Dai Z, Coker OO, Nakatsu G, et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. *Microbiome*. 2018;6(1):70. doi:10.1186/s40168-018-0451-2
27. Tsoi H, Chu ESH, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. *Gastroenterology*. 2017;152(6):1419–1433 e1415. doi:10.1053/j.gastro.2017.01.009
28. Zhou Y, He H, Xu H, et al. Association of oncogenic bacteria with colorectal cancer in South China. *Oncotarget*. 2016;7(49):80794–80802. doi:10.18632/oncotarget.13094
29. Konstantinov SR, Kuipers EJ, Peppelenbosch MP. Functional genomic analyses of the gut microbiota for CRC screening. *Nat Rev Gastroenterol Hepatol*. 2013;10(12):741–745. doi:10.1038/nrgastro.2013.178
30. Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, *Desulfovibrio* and *Enterococcus faecalis* in the feces of patients with colorectal cancer. *J Gastroenterol Hepatol*. 2008;23(8 Pt 1):1298–1303. doi:10.1111/j.1440-1746.2008.05490.x
31. Castellarin M, Warren RL, Freeman JD, et al. *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *Genome Res*. 2012;22(2):299–306. doi:10.1101/gr.126516.111
32. Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of *Fusobacterium* persistence and antibiotic response in colorectal cancer. *Science*. 2017;358(6369):1443–1448. doi:10.1126/science.aal5240
33. Mima K, Nishihara R, Qian ZR, et al. *Fusobacterium nucleatum* in colorectal carcinoma tissue and patient prognosis. *Gut*. 2016;65(12):1973–1980. doi:10.1136/gutjnl-2015-310101
34. Mima K, Cao Y, Chan AT, et al. *Fusobacterium nucleatum* in colorectal carcinoma tissue according to tumor location. *Clin Transl Gastroenterol*. 2016;7(11):e200. doi:10.1038/ctg.2016.53
35. Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of *Fusobacterium nucleatum* to human inhibitory receptor TIGIT protects tumors from immune cell attack. *Immunity*. 2015;42(2):344–355. doi:10.1016/j.immuni.2015.01.010
36. Yang Y, Weng W, Peng J, et al. *Fusobacterium nucleatum* increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappaB, and up-regulating expression of MicroRNA-21. *Gastroenterology*. 2017;152(4):851–866 e824. doi:10.1053/j.gastro.2016.11.018
37. Viljoen KS, Dakshinamurthy A, Goldberg P, Blackburn JM, McDowell A. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between *fusobacterium* spp., enterotoxigenic *Bacteroides fragilis* (ETBF) and clinicopathological features of colorectal cancer. *PLoS One*. 2015;10(3):e0119462. doi:10.1371/journal.pone.0119462
38. Boleij A, Hechenbleikner EM, Goodwin AC, et al. The *Bacteroides fragilis* toxin gene is prevalent in the colon mucosa of colorectal cancer patients. *Clin Infect Dis*. 2015;60(2):208–215. doi:10.1093/cid/ciu787
39. Chung L, Thiele Orberg E, Geis AL, et al. *Bacteroides fragilis* toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. *Cell Host Microbe*. 2018;23(2):203–214 e205. doi:10.1016/j.chom.2018.01.007
40. Thiele Orberg E, Fan H, Tam AJ, et al. The myeloid immune signature of enterotoxigenic *Bacteroides fragilis*-induced murine colon tumorigenesis. *Mucosal Immunol*. 2017;10(2):421–433. doi:10.1038/mi.2016.53
41. Veziant J, Gagniere J, Jouberton E, et al. Association of colorectal cancer with pathogenic *Escherichia coli*: focus on mechanisms using optical imaging. *World J Clin Oncol*. 2016;7(3):293–301. doi:10.5306/wjco.v7.i3.293
42. Feng Q, Liang S, Jia H, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. *Nat Commun*. 2015;6:6528. doi:10.1038/ncomms7528
43. Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. *Oncotarget*. 2016;7(29):46158–46172. doi:10.18632/oncotarget.10064
44. Bonnet M, Buc E, Sauvanet P, et al. Colonization of the human gut by *E. coli* and colorectal cancer risk. *Clin Cancer Res*. 2014;20(4):859–867. doi:10.1158/1078-0432.CCR-13-1343
45. Yoon H, Kim N, Park JH, et al. Comparisons of gut microbiota among healthy control, patients with conventional adenoma, sessile serrated adenoma, and colorectal cancer. *J Cancer Prev*. 2017;22(2):108–114. doi:10.15430/JCP.2017.22.2.108
46. Kinross J, Mirnezami R, Alexander J, et al. A prospective analysis of mucosal microbiome-metabome interactions in colorectal cancer using a combined MAS 1HNMR and metataxonomic strategy. *Sci Rep*. 2017;7(1):8979. doi:10.1038/s41598-017-08150-3
47. Cremonesi E, Governa V, Garzon JFG, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. *Gut*. 2018;67(11):1984–1994. doi:10.1136/gutjnl-2016-313498
48. Yan X, Liu L, Li H, Qin H, Sun Z. Clinical significance of *Fusobacterium nucleatum*, epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. *Onco Targets Ther*. 2017;10:5031–5046. doi:10.2147/OTT.S145949
49. Lennard KS, Goosen RW, Blackburn JM. Bacterially-associated transcriptional remodeling in a distinct genomic subtype of colorectal cancer provides a plausible molecular basis for disease development. *PLoS One*. 2016;11(11):e0166282. doi:10.1371/journal.pone.0166282
50. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. *Gastroenterology*. 2015;148(1):77–87 e72. doi:10.1053/j.gastro.2014.09.038
51. Seppala TT, Bohm JP, Friman M, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. *Br J Cancer*. 2015;112(12):1966–1975. doi:10.1038/bjc.2015.160
52. Manceau G, Marisa L, Boige V, et al. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. *Cancer Med*. 2015;4(3):371–382. doi:10.1002/cam4.370
53. Flanagan L, Schmid J, Ebert M, et al. *Fusobacterium nucleatum* associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. *Eur J Clin Microbiol Infect Dis*. 2014;33(8):1381–1390. doi:10.1007/s10096-014-2081-3

Cancer Management and Research**Dovepress****Publish your work in this journal**

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>